Display options
Cite
Hessin A, Hegazy R, Hassan A, et al. Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats. Open Access Maced J Med Sci. 2015;3(2):195-201doi: 10.3889/oamjms.2015.038.
Hessin, A., Hegazy, R., Hassan, A., Yassin, N., & Kenawy, S. (2015). Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats. Open access Macedonian journal of medical sciences, 3(2), 195-201. https://doi.org/10.3889/oamjms.2015.038
Hessin, Alyaa, et al. "Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats." Open access Macedonian journal of medical sciences vol. 3,2 (2015): 195-201. doi: https://doi.org/10.3889/oamjms.2015.038
Hessin A, Hegazy R, Hassan A, Yassin N, Kenawy S. Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats. Open Access Maced J Med Sci. 2015 Jun 15;3(2):195-201. doi: 10.3889/oamjms.2015.038. Epub 2015 Mar 31. PMID: 27275221; PMCID: PMC4877853.
Copy Download .nbib Format: NLM
Share it on

Open Access Maced J Med Sci. 2015 Jun 15;3(2):195-201. doi: 10.3889/oamjms.2015.038. Epub 2015 Mar 31.

Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats.

Open access Macedonian journal of medical sciences

Alyaa Hessin, Rehab Hegazy, Azza Hassan, Nemat Yassin, Sanaa Kenawy

Affiliations

  1. National Research Center, Medical Division, Pharmacology Department, Giza, Egypt.
  2. Cairo University, Faculty of Veterinary Medicine, Pathology Department, Giza, Egypt.
  3. Cairo University, Faculty of Pharmacy, Pharmacology and Toxicology Department, Cairo, Egypt.

PMID: 27275221 PMCID: PMC4877853 DOI: 10.3889/oamjms.2015.038

Abstract

BACKGROUND: Liver fibrosis is the common pathologic consequence of all chronic liver diseases.

AIM: Lactoferrin (Lf) was investigated for its possible hepatoprotective effect against thioacetamide (TAA)-induced liver fibrosis rat model.

MATERIAL AND METHODS: Rats received TAA (200 mg/kg/biweekly, ip) for four successive weeks. Lf (200 mg/kg/day, p.o.) or vehicle (VHC) was administered for one month before and another month during TAA injection. Body weight and mortality rate were assessed during the month of TAA-intoxication. Thereafter, serum and liver tissues were analyzed for liver function, oxidative, fibrotic and apoptotic markers.

RESULTS: Lf conserved rats against TAA-induced body weight-loss and mortality. Preservation of serum albumin, alkaline phosphatase and total bilirubin levels was also observed. Lf also protected rats against TAA-induced decrease in reduced glutathione and increase in malondialdehyde liver contents. Normal liver contents of hydroxyproline, nuclear factor kappa B and alpha fetoprotein; as markers of fibrosis; were increased with TAA and conserved with Lf-TAA. Lf maintained the normal architecture of the liver and immunohistochemical findings revealed increase in apoptotic bodies compared to TAA that favored necrosis.

CONCLUSION: In conclusion, Lf improved liver function, reduced oxidative stress and liver fibrosis, and enhanced apoptosis in rats with liver fibrosis, suggesting it to have useful therapeutic potential in patients with liver fibrosis.

Keywords: Alpha fetoprotein; Apoptosis; Lactoferrin; Liver fibrosis; NF-κB; Thioacetamide

References

  1. Arch Med Res. 2007 Jan;38(1):15-27 - PubMed
  2. Clin Diagn Lab Immunol. 2001 Nov;8(6):1234-9 - PubMed
  3. Am J Gastroenterol. 2004 Sep;99(9):1708-17 - PubMed
  4. Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8 - PubMed
  5. J Dairy Sci. 2013 Apr;96(4):2095-106 - PubMed
  6. J Physiol Pharmacol. 2008 Aug;59 Suppl 1:107-17 - PubMed
  7. Hepatology. 2007 Aug;46(2):590-7 - PubMed
  8. Indian J Pharmacol. 2011 Feb;43(1):64-8 - PubMed
  9. Curr Opin Crit Care. 2007 Apr;13(2):207-14 - PubMed
  10. Saudi J Gastroenterol. 2012 May-Jun;18(3):155-67 - PubMed
  11. Haematologica. 1995 May-Jun;80(3):252-67 - PubMed
  12. Phytother Res. 2000 Nov;14 (7):522-6 - PubMed
  13. Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36 - PubMed
  14. Arch Pathol Lab Med. 2007 Nov;131(11):1728-34 - PubMed
  15. Ann Surg. 2013 Jan;257(1):27-36 - PubMed
  16. J Hepatol. 2002 Apr;36(4):488-93 - PubMed
  17. World J Gastroenterol. 2012 Mar 14;18(10):1048-58 - PubMed
  18. Arch Biochem Biophys. 1961 May;93:440-7 - PubMed
  19. Gut. 2005 May;54(5):673-81 - PubMed
  20. Eur J Pharm Sci. 2012 Jun 14;46(3):131-41 - PubMed
  21. Evid Based Complement Alternat Med. 2013;2013:157456 - PubMed
  22. Am J Gastroenterol. 2002 Mar;97(3):766-7 - PubMed
  23. Eur J Histochem. 2003;47(4):317-24 - PubMed
  24. J Hepatol. 2006 Feb;44(2):368-74 - PubMed
  25. Hepatology. 2001 Feb;33(2):379-86 - PubMed
  26. Recenti Prog Med. 2011 Jun;102(6):253-60 - PubMed
  27. J Appl Toxicol. 2008 Jan;28(1):35-43 - PubMed
  28. Evid Based Complement Alternat Med. 2013;2013:739850 - PubMed
  29. Cell Mol Life Sci. 2005 Nov;62(22):2588-98 - PubMed
  30. Cancer Sci. 2006 Oct;97(10):1105-10 - PubMed
  31. Infect Immun. 2002 Dec;70(12):7050-3 - PubMed
  32. Hepatology. 2010 Mar;51(3):1007-16 - PubMed
  33. Toxins (Basel). 2010 Jan;2(1):54-68 - PubMed
  34. Basic Res Cardiol. 2000 Aug;95(4):308-15 - PubMed
  35. Evid Based Complement Alternat Med. 2011;2011:103039 - PubMed
  36. Virology. 2014 Mar;452-453:297-302 - PubMed
  37. Biochim Biophys Acta. 2014 Apr 4;1841(4):535-43 - PubMed
  38. Biomark Insights. 2012;7:105-17 - PubMed
  39. Cell Transplant. 2012;21(12):2753-64 - PubMed
  40. Molecules. 2011 Aug 16;16(8):6992-7018 - PubMed
  41. Am J Physiol Gastrointest Liver Physiol. 2002 Jul;283(1):G187-95 - PubMed
  42. Virus Res. 2000 Jan;66(1):51-63 - PubMed
  43. Clin Sci (Lond). 2007 Mar;112(5):265-80 - PubMed
  44. World J Gastroenterol. 2013 Jan 14;19(2):241-8 - PubMed
  45. Hepatology. 2003 May;37(5):1015-25 - PubMed
  46. J Pharm Sci. 1983 May;72(5):465-92 - PubMed
  47. Oncol Lett. 2014 Mar;7(3):820-826 - PubMed
  48. Gynecol Obstet Invest. 2014;77(4):245-9 - PubMed
  49. Int J Mol Sci. 2014 Jan 14;15(1):1003-13 - PubMed
  50. J Autoimmune Dis. 2007 Jun 29;4:3 - PubMed
  51. Hepatology. 2007 May;45(5):1118-28 - PubMed
  52. Arch Pharm Res. 2010 Apr;33(4):601-9 - PubMed
  53. Funct Neurol. 2014 Jan-Mar;29(1):23-9 - PubMed
  54. Gut. 2011 Dec;60(12):1728-37 - PubMed
  55. Toxicol In Vitro. 2010 Dec;24(8):2097-103 - PubMed
  56. Exp Biol Med (Maywood). 2011 Nov;236(11):1306-13 - PubMed
  57. Antimicrob Agents Chemother. 2014;58(1):397-404 - PubMed

Publication Types